Antimicrobial susceptibility of clinical isolates of Haemophilus influenzae to ampicillin-sulbactam

Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):341-4. doi: 10.1016/0732-8893(90)90028-t.

Abstract

A total of 1092 clinical isolates of Haemophilus influenzae (306 type b; 786 non-type-b), from five medical centers were obtained during 1987 and 1988. Disk diffusion antimicrobial susceptibilities were obtained for all isolates, and broth microdilution susceptibilities were obtained for 502 isolates. Beta-lactamase was produced by 34.3% of type-b and 22.1% of non-type-b isolates, with some geographic variations. Using disk diffusion antimicrobial susceptibility testing, all isolates were susceptible to ampicillin-sulbactam, ceftriaxone, cefuroxime, and rifampin; two isolates were resistant to chloramphenicol. Whether tested using a fixed ratio of ampicillin to sulbactam of 2:1 or a fixed concentration of sulbactam, the ampicillin-sulbactam combination demonstrated good activity against clinical isolates of H. influenzae. Only 8 of the 1092 isolates did not produce beta-lactamase but demonstrated MICs of greater than or equal to 2 micrograms/ml for ampicillin.

Publication types

  • Comparative Study

MeSH terms

  • Ampicillin / pharmacology*
  • Ceftriaxone / pharmacology
  • Cefuroxime / pharmacology
  • Chloramphenicol / pharmacology
  • Drug Therapy, Combination / pharmacology
  • Haemophilus influenzae / drug effects*
  • Haemophilus influenzae / enzymology
  • Humans
  • Microbial Sensitivity Tests
  • Multicenter Studies as Topic
  • Rifampin / pharmacology
  • Sulbactam / pharmacology*
  • beta-Lactamases / biosynthesis

Substances

  • sultamicillin
  • Chloramphenicol
  • Ceftriaxone
  • Ampicillin
  • beta-Lactamases
  • Cefuroxime
  • Sulbactam
  • Rifampin